Estramustine

Generic Name: Estramustine

Brand Names: Emcyt

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₁Cl_₂NO_₃

CAS Number: 2998-57-4

Unique Ingredient Identifier: 35LT29625A

Background: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

Indication: For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate

Associated Conditions: Metastatic Prostate Cancer

Associated Therapies: -

Clinical Trials

Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Estramustine
Drug: Tamoxifen

First Posted Date: 2016-08-15

Last Posted Date: 2020-03-09

Lead Sponsor: Institut de Cancérologie de Lorraine

Target Recruit Count: 100

Registration Number: NCT02866955

Locations: 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
🇫🇷
CHU Besançon-Jean Minjoz, Besançon, France

and more 18 locations

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Estramustine
Drug: standard practice

First Posted Date: 2016-08-02

Last Posted Date: 2019-11-18

Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Registration Number: NCT02853071

Locations: 🇫🇷
Centre Hospitalier Régional Universitaire, Besançon, France

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Phase 2

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Doxorubicin
Drug: Ketoconazole
Drug: Docetaxel
Drug: Estramustine
Drug: Degarelix

First Posted Date: 2015-09-25

Last Posted Date: 2018-11-28

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 19

Registration Number: NCT02560051

Locations: 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Doxorubicin
Drug: Ketoconazole
Drug: Docetaxel
Drug: Estramustine

First Posted Date: 2015-07-10

Last Posted Date: 2018-11-27

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 4

Registration Number: NCT02494713

Locations: 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Dexamethasone
Drug: Estramustine
Drug: Zoladex
Drug: Casodex
Procedure: Radical Prostatectomy

First Posted Date: 2010-12-01

Last Posted Date: 2014-02-04

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 28

Registration Number: NCT01250717

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Phase 2

Completed

Conditions: Hormone Resistant Prostate Cancer
Metastatic Prostate Cancer

Interventions: Drug: docetaxel
Drug: estramustine
Drug: prednisone

First Posted Date: 2007-10-10

Last Posted Date: 2009-10-27

Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Target Recruit Count: 150

Registration Number: NCT00541281

Locations: 🇧🇪
Parc Léopold, Brussels, Belgium
🇧🇪
Sint Nilolaus, Eupen, Belgium
🇧🇪
CH Jolimont Lobbes, La-Louvière, Belgium

and more 16 locations

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2010-08-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 100

Registration Number: NCT00193193

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 30

Registration Number: NCT00193271

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

Phase 2

Completed

Conditions: Prostate Adenocarcinoma

First Posted Date: 2005-09-16

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 20

Registration Number: NCT00183924

Locations: 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Prostate Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2018-06-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 62

Registration Number: NCT00165399

Locations: 🇺🇸
University of Massachusetts Memorial Medical Center-University Campus, Worcester, Massachusetts, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy